ACADIA Pharmaceuticals Inc (ACAD.O) News| Reuters.com
Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

31.43USD
24 Jun 2016
Change (% chg)

-- (--)
Prev Close
$31.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,110,330
52-wk High
$51.99
52-wk Low
$16.64

Select another date:

Tue, May 31 2016

BRIEF-Acadia's Nuplazid available for treatment of hallucinations, delusions associated with Parkinson's

* Nuplazid (pimavanserin) now available for treatment of hallucinations and delusions associated with Parkinson's disease psychosis Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Acadia Pharmaceuticals reports Q1 loss per share $0.45

* Acadia pharmaceuticals reports first quarter 2016 financial results

U.S. approves first drug for psychosis linked to Parkinson's

Acadia Pharmaceuticals Inc's drug for psychosis linked to Parkinson's disease was approved in the United States on Friday, becoming the first treatment for the condition to get a nod in the country.

Acadia drug approval could clear way for Axovant dementia therapy

An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.

Acadia drug approval could clear way for Axovant dementia therapy

April 28 An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.

FDA panel backs Acadia drug for psychosis linked to Parkinson's

An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc's drug for psychosis related to Parkinson's disease.

UPDATE 2-FDA panel backs Acadia drug for psychosis linked to Parkinson's

March 29 An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc's drug for psychosis related to Parkinson's disease.

BRIEF-Acadia Pharma says FDA panel votes 12 to 2 on benefit-risk profile of its drug for Parkinson's Disease psychosis

* Fda advisory committee votes 12 to 2 that benefits of acadia pharmaceuticals' nuplazid(tm) (pimavanserin) for the treatment of psychosis associated with parkinson's disease outweigh the risks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Select another date: